277 related articles for article (PubMed ID: 28776237)
1. Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.
Skor H; Smith EB; Loewen G; O'Brien CF; Grigoriadis DE; Bozigian H
Drugs R D; 2017 Sep; 17(3):449-459. PubMed ID: 28776237
[TBL] [Abstract][Full Text] [Related]
2. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine.
Brar S; Vijan A; Scott FL; Jimenez R; Zhang H; Grigoriadis DE; Loewen G
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):447-456. PubMed ID: 36530055
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers.
Schneider F; Bradbury M; Baillie TA; Stamler D; Hellriegel E; Cox DS; Loupe PS; Savola JM; Rabinovich-Guilatt L
Clin Transl Sci; 2020 Jul; 13(4):707-717. PubMed ID: 32155315
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
9. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
Schneider F; Stamler D; Bradbury M; Loupe PS; Hellriegel E; Cox DS; Savola JM; Gordon MF; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):647-659. PubMed ID: 33038289
[TBL] [Abstract][Full Text] [Related]
11. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
12. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
14. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
[No Abstract] [Full Text] [Related]
15. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies.
Mehvar R; Jamali F; Watson MW; Skelton D
Drug Metab Dispos; 1987; 15(2):250-5. PubMed ID: 2882986
[TBL] [Abstract][Full Text] [Related]
17. Valbenazine: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
[TBL] [Abstract][Full Text] [Related]
18. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
20. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
